Dopamine D3 receptor and Dopamine D4 receptor (DRD3, DRD4)

Dopamine D3 receptor (DRD3) and dopamine D4 receptor (DRD4) are both part of the D2-like subfamily of G protein-coupled dopamine receptors, with distinct genetics and pharmacological profiles. Both are predominantly expressed in the limbic and prefrontal areas of the brain, and are implicated in the regulation of emotion, cognition, motivation, and reward. DRD3 is especially implicated in the pathophysiology and treatment of neuropsychiatric and substance use disorders, with antagonists explored for antipsychotic and anti-addiction effects. DRD4 is notable for its genetic polymorphisms, variability among individuals, and links to ADHD. Drugs targeting these receptors aim to modulate neurotransmission with the goal of improving symptoms in schizophrenia, Parkinson’s disease, substance abuse, and other neuropsychiatric conditions. Selectivity for D3/D4 over D2 may reduce certain motor and side-effect liabilities, but challenges remain in achieving receptor-specific effects and predicting patient response[1][2][4][7][10].

Other names

Dopamine receptor D3DRD3D3 receptorDopamine receptor D4DRD4D4 receptor

Agonists or partial agonists stimulate the receptor, modulating neurotransmission, improving motor and non-motor symptoms (e.g., in Parkinson’s disease)[7] Antagonists block the receptor, reducing psychotic symptoms and potentially improving cognitive and negative symptoms in schizophrenia, and reducing addictive behavior/substance seeking[2][7][10] Multi-target compounds may act on several dopamine receptor subtypes for broader symptom control[2]